Bing Guo, PhD

• Act as subject matter expert for qPCR methods and proactively prepare quality control analysts for clinical trials. • Develop and author improved alternative qPCR methods for Transgene copy number quantification and Residual viral particle detection to substitute registered analytical methods. cGMP trainer of quality control analysts on newly developed methods. Write validation protocols and validation reports. Manage and oversee execution of method validation related activities. • Lead developer of genetic identity assay method using Capillary Electrophoresis technology. • Play critical roles to bring two qPCR testing methods onsite saving millions of dollars for the Cell and Gene Therapies unit. Coordinate cGMP qPCR laboratory design, construction, and qualification activities. Manage equipment acquisition and qualification. Author and revise standard operating procedures (SOPs). Lead author of method transfer protocol and assist execution of method transfer. • Manage change controls and collaborate with regulatory to support IND amendments.

• Led multiple discovery projects and identified oncology drug candidates. • Team leader in a matrix team working on cutting-edge cancer stem-cell isolation and characterization. • Established early colorectal patient derived xenograft (PDX) models and led expansion of the oncology research unit’s in vivo model system. Pioneered FACS sorting of colorectal PDX cells and in vivo testing of tumor forming abilities. • Successfully enriched cells with cancer stem cell properties and built two collaboration teams carrying out gene profiling and metabolite profiling of cancer stem cells resulting in three promising oncology targets. • Led efforts on PKN3 kinase assay development (ELISA) and MCT4 target validation and mechanism of action study strengthening research unit’s pipeline. • Initiated cancer metabolism target hexokinase II project, overseeing both internal and external contract research organization (CRO) efforts.

• Gained expertise in small molecule drug development. • Developed PDK1 kinase assay (TR-FRET) for high throughput screen of small molecule compounds. Carried out high throughput screen for PDK1 kinase inhibitors. • Developed ELISA assay for further characterization of PDK1 kinase inhibitors. Characterized different subgroups of PDK1 kinase inhibitors. • Advanced small subgroups of inhibitors for the Discovery phase of development. • Led biology discovery team. Coordinated collaboration with medicinal chemists and in vivo pharmacologists.

Dr. Gerald R. Fink’s laboratory • Studied signal transduction and cell surface proteins for fungal pathogenesis. • Improvised yeast pathogenesis phenotype screening leading to the identification of adhesive cell wall proteins. • Systemically modified expression of a series of yeast cell surface proteins by genetic method. • Investigated cell surface proteins involved in flocculation, filamentation, invasion, and mating and found that many of these proteins were interchangeable (Proc. Natl. Acad. Sci. USA 97:12158-12163). Studied signal transduction and cell surface proteins for fungal pathogenesis.

Dr. Kim T. Arndt’s laboratory • Conducted genetic research on response of yeast to nutrients. • Performed yeast genetic screens including mutant suppressor screen and two-hybrid screen. • Carried out genetic studies on genes from two-hybrid screen (Mol. Cell 8:1017-1026).

Dr. Elizabeth A. Leibold’s laboratory • Studied iron homeostasis regulation in mammalian cells. • Developed expertise in protein purification: purified iron regulatory protein 2 (IRP2) by conventional ion-exchange chromatography, FPLC, and RNA affinity chromatography. • Obtained molecular biology expertise: determined peptide sequence from purified IRP2 protein, cloned IRP2 cDNA through library screen and PCR based sequence extension, overexpressed a unique region of IRP2 in bacteria and obtained purified protein to inject into rabbit for antibody production, and produced IRP2 specific antibodies. • Performed biochemical characterization of IRP2 and studied its unique regulation through proteasome degradation in response to cellular iron levels.